SRC
REGN icon

Shufro Rose & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Shufro Rose & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Hold
0
– -$285K – 318
2024
Q4 		– Hold
0
– – – 233
2022
Q1 		– Sell
-500
Closed -$316K – 357
2021
Q4 		$316K Buy
+500
New +$307K 0.02% 220

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Shufro Rose & Co's REGN Position: Q2 2026 in Review

Shufro Rose & Co increased its Regeneron Pharmaceuticals (REGN) stake by 0.15% in Q2 2026, buying an estimated $2.72K and bringing the position to 2,602 shares worth $1.62M. The position accounts for 0.09% of the portfolio, ranked #94.

Shufro Rose & Co first reported a position in REGN in Q1 2016 and has held it in 36 quarters since. The position peaked at $2.03M in Q4 2025. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Shufro Rose & Co held 2,602 shares of Regeneron Pharmaceuticals worth $1.62M as of Q2 2026.
  • Shufro Rose & Co bought 4 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.72K.
  • Regeneron Pharmaceuticals made up 0.09% of Shufro Rose & Co's portfolio in Q2 2026, its #94 holding.
  • Shufro Rose & Co first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 36 quarters since.
  • Shufro Rose & Co's Regeneron Pharmaceuticals position peaked at $2.03M in Q4 2025.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Shufro Rose & Co's 13F filing for Q2 2026, filed 12 Aug 2026.